TOPICS 2018
-
Dr. Masato Hosokawa (Dementia Research Project) was awarded the 2nd Serika fund for ALS research.
-
Tomoyuki Miyashita published a paper on ”Long-term memory encoding engram neurons are established by the transcriptional cycling” in Cell Reports.
-
Notice with respect to a license agreement with uniQure and the development of gene therapy encoding a new enzyme, “modified NAGA”, for Fabry disease
-
Masaki Oba (Diabetic Neuropathy Project) had won the Junior Investigator Poster Award of the 41st annual meeting of the Japan Neuroscience Society and the Young Investigator Award of the 28th annual meeting of Japanese Society of Pathophysiology
-
Shinobu Hirai, Haruo Okado (Neural Development Project) with Koji Hotta（keio University） published a paper on “Developmental roles and evolutionary significance of AMPA-type glutamate receptors” in BioEssays.
-
Takeru Honda, PhD, (Motor Disorders Project) published a paper on “Tandem Internal Models Execute Motor Learning in the Cerebellum” in PNAS.
-
Chiaki Ohtaka-Maruyama, PhD, (Neural Network Project) published a paper on “Synaptic communication controls neuronal migration” in Science.
-
Yuichiro Miyaoka, PhD, (Regenerative Medicine Project) published a paper on “New way to enhance precise genome editing via HDR induced by CRISPR/Cas9” in Nucleic Acids Research.
-
Dr.Atsushi Nishida, (Mental Health Promotion Project) published a paper in Journal of Psychiatry Research.
-
Nature Index 2018 Japan announced the tables which show Japan’s leading institutions, our institute ranked first in "life science" field
-
Dr. Miharu Nakanishi of Mental Health Promotion Project and Mental Health and Nursing Research Team had made a presentation in the Japan-UK Dementia Conference.
-
Hikaru Tsuchiya, PhD, published a paper on “A novel versatile method for assessing chain length of substrate-attached polyubiquitin chains” in Nature Communications.
-
Fumiaki Ohtake, Ph.D. published a paper on “K63 ubiquitylation triggers proteasomal degradation by seeding branched ubiquitin chains” in PNAS.
-
Dr. Koji Yamano, published a paper on “Elucidation of a new mechanism in which damaged mitochondria are degraded through autophagy machinery” in Elife.
-
Masanari Itokawa published a paper on “Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress.” in Psychiatry and clinical neuroscience.
HOME ＞ Topics2018 ＞ 11 Jan 2018
11 January 2018
Masanari Itokawa (CMRC), Mitsuhiro Miyashita (Schizophrenia Research Project) published a paper on “Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress.” in Psychiatry and clinical neuroscience.
Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress.
【Aim】 We previously reported that increased pentosidine (enhanced carbonyl stress) is associated with a subpopulation of patients with schizophrenia. Pyridoxamine, one of the three forms of vitamin B6, is able to entrap pentosidine and excrete them. The aim of this clinical study is to obtain proof of concept of high-dose pyridoxamine as a novel treatment option for schizophrenia with enhanced carbonyl stress.
【Methods】 Ten Japanese patients diagnosed as schizophrenia showing high plasma pentosidine were recruited in a 24 week, open trial in which high-dose pyridoxamine (ranging from 1200 to 2400 mg/day) was added on a conventional anti-psychotic regimen. Major Outcomes were the total change in Positive and Negative Syndrome Scale (PANSS) score and the Brief Psychiatric Rating Scale (BPRS) score from baseline to end of treatment at week 24 (or at withdrawal). Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) and Columbia-Suicide Severity Rating Scale (C-SSRS) were evaluated to determine the severity of extrapyramidal symptoms (EPS) and the occurrence of suicide related adverse events
【Results】 Decrease of plasma pentosidine levels were observed in eight patients. Two patients showed marked improvement in their psychological symptoms. A patient who harbors a frameshift mutation in the Glyoxalase 1 (GLO1) gene also showed moderate reduction in psychosis with a considerable decrease in pentosidine levels. An improvement of drug induced Parkinsonism occurred in four patients. Although there was no severe suicide associated ideation or behavior, Wernicke’s encephalopathy-like adverse drug reactions occurred in two patients, which was completely suppressed by rapid thiamine supplementation.
【Conclusion】 High-dose pyridoxamine add-on treatment may be, in part, effective for schizophrenia with enhanced carbonyl stress. Further randomized, placebo controlled study with should be required to confirm the efficacy of high-dose pyridoxamine for these patients.
- ＜Title of the paper＞
- Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress.
Psychiatry Clin Neurosci. 2018 Jan;72(1):35-44. doi: 10.1111/pcn.12613.
PDF
- ＜Journal＞
- JPsychiatry and clinical neuroscience. (January 2018)
Schizophrenia Research Project ▶
